5 minutes on the leukemia landscape with Dr Elias Jabbour

Dr Elias Jabbour, MD Anderson Cancer Center, Texas, USA, provides insight on recent developments in the management of leukemia, in particular, Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Watch as he discusses:

• unmet needs for people with Ph+ ALL
• recent practice-changing updates
• the importance of a multidisciplinary approach
• the future for people with Ph+ ALL

What unmet needs remain for patients with Ph+ ALL, and how are these being addressed?

What practice-changing updates from the 2023 ASCO^® Annual Meeting do you think will have the biggest impact on the treatment and management of leukemia?

How can other healthcare professionals, such as GPs and nurse practitioners, help to address patient needs?

What does the future look like for people with Ph+ ALL?

What are your key takeaways from this symposium on the frontline treatment of Ph+ ALL?

Elias Jabbour, MD (Chair)

Dr. Jabbour joined the MD Anderson Cancer Center faculty in 2007 and is currently a Professor of Medicine in the Department of Leukemia. He is actively involved in developmental therapeutics research in leukemia.

Over the past 5 years, Dr. Jabbour has assisted in developing chemotherapeutic and biologic agents in leukemias and has contributed to the development of others, including the Hyper CVAD-ofatumumab regimen in ALL, clofarabine in myeloid malignancies, hypomethylating agents in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), tyrosine kinase therapy in chronic myeloid leukemia (CML), and triple therapy in AML.

Dr. Jabbour has authored or co-authored hundreds of peer-reviewed medical publications and has served on the editorial boards of several scientific journals.